Featured Post from Aston University

Manuka honey could help to clear deadly drug-resistant lung infection – research

Sep 8, 2022

4 min

Dr Jonathan A. G. Cox



• Scientists develop a potential nebulisation treatment using manuka honey to clear a drug resistant lung infection that can be fatal in cystic fibrosis patients

• Aston University researchers combined the antibiotic amikacin with manuka honey as a novel treatment for Mycobacterium abscessus

• Using the manuka honey combination resulted in an eight-fold reduction in the dosage of the antibiotic


A potential new treatment combining natural manuka honey with a widely used drug has been developed by scientists at Aston University to treat a potentially lethal lung infection and greatly reduce side effects of one of the current drugs used for its treatment.


The findings, which are published in the journal Microbiology, show that the scientists in the Mycobacterial Research Group in the College of Health and Life Sciences at Aston University were able to combine manuka honey and the drug amikacin in a lab-based nebulisation formulation to treat the harmful bacterial lung infection Mycobacterium abscessus.


Manuka honey is long known to have wide ranging medicinal properties, but more recently has been identified for its broad spectrum antimicrobial activity. Now scientists have found that manuka honey has the potential to kill a number of drug resistant bacterial infections such as Mycobacterium abscessus – which usually affects patients with cystic fibrosis (CF) or bronchiectasis.


According to the Cystic Fibrosis Trust, CF is a genetic condition affecting around 10,800 people - one in every 2,500 babies born in the UK -and there are more than 100,000 people with the condition worldwide. The NHS defines bronchiectasis as a long-term condition where the airways of the lungs become widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection..

In the study, the researchers used samples of the bacteria Mycobacterium abscessus taken from 16 infected CF patients. They then tested the antibiotic amikacin, combined with manuka honey, to discover what dosage was required to kill the bacteria.


As part of the study the team used a lab-based lung model and nebuliser - a device that produces a fine spray of liquid often used for inhaling a medicinal drug. By nebulising manuka honey and amikacin together, it was found they could improve bacterial clearance, even when using lower doses of amikacin, which would result in less life-changing side-effects to the patient.


In the UK, of the 10,800 people living with CF, Mycobacterium abscessus infects 13% of all patients with the condition. This new approach is advantageous not only because it has the potential to kill off a highly drug resistant infection, but because of the reduced side effects, benefitting quality of life and greatly improving survival chances for infected CF patients.


Mycobacterium abscessus is a bacterial pathogen from the same family that causes tuberculosis, but this bug differs by causing serious lung infections in people (particularly children) with pre-existing lung conditions, such as CF and bronchiectasis, as well as causing skin and soft tissue infections. The bacteria is also highly drug resistant.


Currently, patients are given a cocktail of antibiotics, consisting of 12 months or more of antimicrobial chemotherapy and often doesn’t result in a cure. The dosage of amikacin usually used on a patient to kill the infection is 16 micrograms per millilitre. But the researchers found that the new combination using manuka honey, required a dosage of just 2 micrograms per millitre of amikacin - resulting in a one eighth reduction in the dosage of the drug.


Until now Mycobacterium abscessus has been virtually impossible to eradicate in people with cystic fibrosis. It can also be deadly if the patient requires a lung transplant because they are not eligible for surgery if the infection is present.


Commenting on their findings, lead author and PhD researcher Victoria Nolan said:


"So far treatment of Mycobacterium abscessus pulmonary infections can be problematic due to its drug resistant nature. The variety of antibiotics required to combat infection result in severe side effects.

"However, the use of this potential treatment combining amikacin and manuka honey shows great promise as an improved therapy for these terrible pulmonary infections.

“There is a need for better treatment outcomes and in the future we hope that this potential treatment can be tested further.”


Dr Jonathan Cox, senior lecturer in microbiology, Aston University said:


“By combining a totally natural ingredient such as manuka honey with amikacin, one of the most important yet toxic drugs used for treating Mycobacterium abscessus, we have found a way to potentially kill off these bacteria with eight times less drug than before. This has the potential to significantly reduce amikacin-associated hearing loss and greatly improve the quality of life of so many patients – particularly those with cystic fibrosis.

“I am delighted with the outcome of this research because it paves the way for future experiments and we hope that with funding we can move towards clinical trials that could result in a change in strategy for the treatment of this debilitating infection.”


Dr Peter Cotgreave, chief executive of the Microbiology Society said:


"The Microbiology Society is proud to support the scientific community as it explores innovative solutions to overcome the growing global challenge of antimicrobial resistance. This study demonstrates one of many ways in which microbiologists are pioneering new methods to tackle drug-resistant infections, by incorporating natural products, like manuka honey, into existing therapies."


For more information about the School of Biosciences, please visit our website.



Connect with:
Dr Jonathan A. G. Cox

Dr Jonathan A. G. Cox

Lecturer in Microbiology

Dr Cox's research interests surround the discovery of new antibiotics & identifying the mechanisms by which those antibiotics kill bacteria.

Health SciencesBiochemistryAntibioticsAntimicrobial ResistanceMicro-Organisms
Powered by

You might also like...

Check out some other posts from Aston University

Twin earthquakes in Venezuela raise serious concerns over humanitarian, health and infrastructure impacts featured image

3 min

Twin earthquakes in Venezuela raise serious concerns over humanitarian, health and infrastructure impacts

Dr Komal Raj Aryal, lecturer in crisis and disaster management at Aston Business School, has expressed serious concern following the powerful twin earthquakes that struck northern Venezuela on 24 June 2026. "The back-to-back earthquakes, measuring magnitude 7.2 and 7.5 and occurring within less than a minute of each other at an approximate depth of 22 km, represent an exceptionally severe seismic event," said Dr Aryal, who has more than 26 years of international research experience in earthquakes, landslides, extreme weather events and disaster risk governance. "The combination of two major earthquakes occurring in rapid succession, their relatively shallow depths, and the repeated strong ground shaking is likely to have substantially increased damage to buildings, transport networks and other critical infrastructure. Scientifically, a magnitude 7.5 earthquake releases approximately three times more energy than a magnitude 7.2 event. Experiencing both events within seconds creates an extremely complex emergency response situation." Dr Aryal highlighted particular concern for San Felipe, an important industrial, commercial and transportation centre with a population of more than 300,000 people. Built across hilly terrain, with steep streets and dense urban development, the city could face significant challenges for emergency access, search and rescue operations, evacuation and humanitarian assistance. Around 10% of the city's population is aged 65 or older, making older adults particularly vulnerable during prolonged emergency situations. "If widespread power outages occur while temperatures remain between 32°C and 35°C, communities will face compounded risks including heat stress, disruption to healthcare services, shortages of clean water, communication failures and interruptions to essential public services. These cascading impacts often become as significant as the direct earthquake damage itself." Based on the available seismic information and preliminary footage shared on social media, Dr Aryal noted that it will likely take days or even weeks before authorities fully understand the extent of structural damage across northern Venezuela. "Initial seismic information suggests a rupture along a major fault system parallel to Venezuela's northern coastline, with areas experiencing extremely intense ground shaking. If confirmed, significant cascading impacts may extend well beyond the epicentral area, affecting multiple urban centres, transport corridors and regional supply chains." Dr Aryal also expressed concern about the resilience of Venezuela's healthcare system. "Northern Venezuela contains a large concentration of hospitals and healthcare facilities. At present, it remains unclear how many medical facilities have been affected by the earthquakes. Any disruption to hospitals, combined with existing pressures on healthcare capacity, medicine supplies and emergency logistics, could significantly affect the delivery of healthcare services for both acute injuries and patients with chronic illnesses." He added that damage to airports, major highways, bridges and other transport infrastructure could delay humanitarian assistance, emergency logistics and economic recovery. "The humanitarian consequences of this disaster will depend not only on the severity of the ground shaking, but also on the resilience of critical infrastructure, the effectiveness of emergency coordination, the availability of healthcare services and the country's broader socioeconomic capacity to recover." Dr Aryal further warned that the immediate earthquake sequence is unlikely to mark the end of the crisis. "Strong aftershocks are highly likely following earthquakes of this magnitude. These may continue for months, and some could themselves be damaging. They increase risks to already weakened buildings, complicate search and rescue operations, trigger additional landslides in mountainous areas, and prolong humanitarian needs." He concluded that while casualty figures and the full extent of the damage remain uncertain, the event has the potential to become one of the most significant seismic disasters in the region in recent years, requiring sustained national and international humanitarian support.

The world is burning useful waste, and cleaner alternatives are needed featured image

4 min

The world is burning useful waste, and cleaner alternatives are needed

When we talk about clean air, the conversation usually turns to traffic: exhaust fumes, congestion, school runs and the air people breathe on busy streets. That focus is understandable because road transport remains one of the most visible sources of poor air quality in everyday life. But Clean Air Day should also draw attention to a less visible question: why are useful materials still being burned as waste? Clean air is about more than traffic Around the world, huge quantities of leftover straw are still treated as waste to be cleared quickly, with rice straw one of the clearest examples. More than 700 million tonnes of rice straw are produced globally every year, and around 80% is burned. That contributes directly to air pollution and greenhouse gas emissions, while also destroying material that could have value. At Aston University’s Energy and Bioproducts Research Institute, researchers are exploring alternatives to open burning of crop residues, including whether materials often treated as waste could instead become useful sources of energy, fuels or bioproducts. This matters because the clean air debate needs to look beyond transport. How we manage waste, land and energy also plays a part, and agricultural residues should not automatically be seen as rubbish to be burned. In many cases, they could be resources with real value. Why burning crop waste matters The World Health Organization describes air pollution as one of the greatest environmental risks to health, estimating that ambient outdoor air pollution caused 4.2 million premature deaths globally in 2019. Much of that risk comes from exposure to fine particulate matter, which is linked to cardiovascular and respiratory disease and cancers. That is particularly relevant when residues are burned in the open, as smoke and fine particles can travel beyond the field where burning takes place, affecting nearby communities and wider air quality. There is a practical issue as well as an environmental one. If burning is the fastest and cheapest way to clear land, it can easily become the default, which is why any cleaner alternative has to work for farmers and communities in practice. It is not enough to tell people to stop burning; they need practical alternatives that make sense economically and locally. Turning waste into cleaner alternatives Biochar and bioenergy are two examples of how waste crop material can be treated differently. Instead of being burned in the open, residues can be converted into useful products or sources of renewable energy. Biochar can also offer practical benefits for farmers when it is produced and applied appropriately. Studies have shown that addition of biochar to the soil can improve its structure, help retain nutrients and, in some cases, reduce the need for synthetic fertilisers, which will lower associated emissions and economic demands. The water-holding capacity of biochar can also support crops during dry periods, potentially reducing irrigation demand in drought-prone seasons. Work connected to rice straw has shown that cleaner alternatives to burning can produce measurable environmental benefits while supporting local economies. Community-scale rice straw bioenergy systems, for example, can avoid 2.7–3.5 tonnes of CO₂ equivalent emissions per hectare each year, while creating fuel savings and reducing post-harvest losses for rice farming communities. Research and interviews have shown that farmers and local stakeholders are willing to participate in these transitions when alternatives are designed around their needs and priorities. During community engagement activities, participants consistently highlighted cleaner air as an important benefit, not only for environmental reasons but also because of concerns about the health impacts of smoke and the financial burden of illness. For many households, avoiding respiratory problems and expensive hospital bills was seen as just as important as generating additional income from agricultural residues. That matters because cleaner air is linked to more than one policy area. Transport is important, but so are farming, energy and waste. Research can help identify what works, where the trade-offs are, and how promising ideas can move beyond the lab. It can also support industry, policymakers and local partners to develop alternatives that are practical rather than theoretical. For policymakers, the lesson is that air quality cannot be improved by focusing only on the most visible sources of pollution. Transport matters, but so do homes, industry, farming, waste and energy systems. There is no single answer. Agricultural residues vary, local conditions vary, and technologies need to be assessed carefully, but cleaner air will require better options than burning. Clean Air Day should prompt us to ask why useful materials are still being burned in the first place. If we want cleaner air, we need to reduce what we burn and get smarter about what we waste. This article was written by Dr Samuel Sogbesan and Thea Mae Baltazar from Aston University’s Energy and Bioproducts Research Institute. (Photo by Sandie Peters on Unsplash)

Major trial shows increasing bone density fails to cut fracture risk in brittle bone disease featured image

3 min

Major trial shows increasing bone density fails to cut fracture risk in brittle bone disease

An international clinical trial involving Aston University researchers has challenged long held assumptions about how brittle bone disease is treated in adults, after finding that substantially increasing bone density did not reduce the risk of fractures. The study, published in the Journal of the American Medical Association (JAMA), examined whether a two stage treatment using the bone building drug teriparatide followed by the bone preserving drug zoledronic acid could reduce fractures in adults with osteogenesis imperfecta, often referred to as brittle bone disease, a rare genetic condition that causes bones to break easily throughout life. Researchers followed 349 adults treated at 27 specialist centres across the UK and Europe. While the treatment led to clear increases in bone density in the spine and hip, fracture rates were no lower than among patients receiving standard care, suggesting that bone quality may matter more than bone density alone in preventing fractures in people with the condition. The findings underline a key distinction between brittle bone disease and more common bone conditions such as osteoporosis, where increasing bone density is known to reduce fracture risk. In osteogenesis imperfecta, the study suggests that bones can become denser without becoming less likely to break, indicating that the underlying quality and structure of bone tissue may play a greater role in fracture risk than density alone. Dr Zaki Hassan Smith, an endocrinologist at Aston Medical School who contributed to the research, said: “This study shows that in osteogenesis imperfecta, simply increasing bone density doesn’t necessarily translate into fewer fractures. That’s important, because it tells us that the disease is more complex than what we see on a scan. The findings help shift the focus towards understanding bone quality and how bones behave in real life, which is essential if we are to develop more effective treatments that genuinely reduce harm for patients.” Osteogenesis imperfecta is a genetic condition that affects collagen, leaving bones fragile and prone to fracture throughout life. There is currently no licensed treatment specifically approved to prevent fractures in adults with the condition, and patients often experience repeated fractures, chronic pain and long term disability. The trial tested a sequential treatment strategy commonly used in osteoporosis, where a bone building drug is followed by a treatment designed to preserve gains in bone strength. Although this approach successfully increased bone density in people with osteogenesis imperfecta, it did not reduce fracture rates, suggesting that treatment strategies effective in osteoporosis may not directly translate to rare bone diseases. Researchers did observe improvements in some quality of life measures among participants receiving the treatment, including reduced pain interference and improved mobility. However, fracture prevention remained unchanged, reinforcing the need for new approaches that target the fundamental properties of bone in osteogenesis imperfecta rather than density alone. The study was led by the University of Edinburgh and funded by the Medical Research Council and the National Institute for Health and Care Research. Aston University contributed clinical and academic expertise through Aston Medical School as part of the large international collaboration, which involved specialist centres across the UK and Europe. The study was led by the University of Edinburgh, with Aston University contributing clinical and academic expertise as part of a wider international collaboration involving multiple specialist centres across the UK and Europe. The research was funded by the Medical Research Council and the National Institute for Health and Care Research. Researchers say the findings provide important guidance for future research, helping to steer efforts towards treatments that focus on bone quality, strength and resilience in everyday life. They also highlight the value of large scale clinical trials in rare diseases, where learning what does not reduce harm is an essential step towards better care. The paper, Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta, is published in JAMA. https://doi.org/10.1001/jama.2026.6889

View all posts
Powered by